Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q3 2022 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Medicenna Therapeutics Corp. (NASDAQ:MDNA) Q3 2022 Earnings Conference Call February 9, 2022 8:30 AM ET

Company Participants

Fahar Merchant - President & CEO

Liz Williams - CFO

Martin Bexon - CMO

Rosemina Merchant - CDO

Dan Ferry - LifeSci Advisors, IR

Conference Call Participants

Matt Biegler - Oppenheimer & Co. Inc.

David Martin - Bloom Burton

Swayampakula Ramakanth - H.C. Wainwright & Co.

Shubhendu Roy - Brookline Capital Markets

David Bautz - Zacks Small-Cap Research.


Greetings, and welcome to Medicenna Therapeutics Third Quarter Fiscal 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator instructions]. As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Dan Ferry of LifeSci Advisors. Please go ahead.

Dan Ferry

Thank you, operator, and thank you all for participating in today's conference call. This morning, Medicenna issued a press release providing financial results and corporate updates for the quarter ended December 31, 2021. If you have not yet seen the press release, it is available on the Investors page of Medicenna’s website.

Before we begin, I would like to remind you that certain statements and information shared during this call constitute forward-looking information within the meaning of applicable securities laws and relate to the future operations of the company, and other statements that are not historical facts, including statements related to, the clinical potential and development of the MDNA11, including expected milestones, MDNA55, and BiSKITs programs, the potential of the Superkine platform, partnering activities, cash runway, and the presentation of additional data.

All statements other than statements of historical fact included in this conference call, including the future plans and objectives of the company, are forward-looking statements that are subject to risks and

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.